Advertisement
YOU ARE HERE: LAT HomeCollectionsViratek Inc
IN THE NEWS

Viratek Inc

FEATURED ARTICLES
ARTICLES BY DATE
BUSINESS
November 12, 1994 | From Times Staff and Wire Reports
ICN Merger Complete: Costa Mesa-based ICN Pharmaceuticals Inc. said Friday that it has completed its merger with three affiliated corporations: SPI Pharmaceuticals, ICN Biomedicals and Viratek. Each share of pre-merger ICN Pharmaceuticals stock will be converted to 0.512 share of new ICN common stock. Each share of SPI stock will be converted to a full share of new ICN common stock. Viratek shares will be converted at the rate of one for each 0.
Advertisement
BUSINESS
November 2, 1994 | HOPE HAMASHIGE, SPECIAL TO THE TIMES
Creating a corporation with $500 million in annual sales, shareholders of ICN Pharmaceuticals and three affiliates on Tuesday approved a merger of the four into a single company. ICN said it expects federal regulators to give their approval next week for its combination with Viratek Inc., SPI Pharmaceuticals and ICN Biomedicals. The new company will operate under the name ICN Pharmaceuticals, and its stock will be traded on the New York Stock Exchange.
BUSINESS
August 3, 1994 | DEBORA VRANA, TIMES STAFF WRITER
ICN Pharmaceuticals in Costa Mesa said Thursday that it plans to streamline its operations by merging with its three affiliates, creating a new company with $500 million in annual sales. If shareholders and federal regulators approve the proposal, the new company, which will keep the name ICN Pharmaceuticals, would begin trading on the New York Stock Exchange this fall.
BUSINESS
August 3, 1994 | DEBORA VRANA, TIMES STAFF WRITER
To streamline its operations, ICN Pharmaceuticals Inc. said Tuesday that it plans to merge with its three affiliates, creating a new company with $500 million in annual sales. If shareholders and federal regulators approve the proposal, the new company, which would keep the name ICN Pharmaceuticals, would begin trading on the New York Stock Exchange this fall.
BUSINESS
November 19, 1992 | From Times Staff and Wire Reports
Viratek of Costa Mesa Plans Shelf Offering: Viratek Inc., the developer of therapeutic pharmaceuticals, plans a shelf offering of 1.25 million units at $8.50 each, according to a filing Wednesday with the Securities and Exchange Commission.
Los Angeles Times Articles
|